The Latest

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    Two biotechs — radiopharmaceuticals specialist Full-Life Technologies and immune drugmaker Accro Bioscience — raised $160 million combined in a pair of equity financings announced Monday.

    Updated May 19, 2026
  • Drug manufacturing process
    Image attribution tooltip
    volodyar via Getty Images
    Image attribution tooltip
    Sponsored by Cencora

    Unlocking more value from mature drug products through strategic outsourcing

    See how strategic outsourcing can maximize value and reduce costs for mature drug portfolios.

  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly snaps up Engage to advance non-viral genetic medicines

    The acquisition is Lilly’s latest push into genetic medicine, giving it a technology designed to overcome some of the field’s longstanding limitations.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

    Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.

  • People seen walking down Wall Street.
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    A migraine drugmaker heads to the public markets through reverse merger

    Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.

  • An illustration of Red and white blood cells inside a vein or artery.
    Image attribution tooltip
    SpiffyJ via Getty Images
    Image attribution tooltip

    Relay drug shows early promise against rare blood vessel diseases

    While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments.

  • A Regeneron sign in front of a building.
    Image attribution tooltip
    Courtesy of Regeneron Pharmaceuticals
    Image attribution tooltip

    Regeneron immunotherapy combo comes up short in melanoma trial

    A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.

  • Corporate logos are seen outside on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    FDA approves AstraZeneca’s new kind of hypertension drug

    Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in annual sales.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug

    The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Parabilis Medicines, a well-funded startup chasing “undruggable” cancer drug targets, has become the latest biotech to publicly reveal IPO plans.

    Updated May 20, 2026
  • A white office building bearing a sign for BioMarin Pharmaceutical stands against a blue sky.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    BioMarin drug acquired in buyout misses goal in rare disease study

    Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects. 

  • Endometrial cancer cells in the uterus or cervix womb neck - closeup view 3d illustration
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    Merck ADC, licensed from China, hits mark in first big global trial

    The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next decade.

  • An image of sodium ion channels
    Image attribution tooltip
    Permission granted by Stephanie Shiers, The University of Texas at Dallas
    Image attribution tooltip
    Deep Dive // Pain drugs

    A year after Vertex’s big launch, pain drug research faces a pivotal moment

    Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?

  • India flag building
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    India’s pharma industry is going global. But can it catch up to China?

    A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.

  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA hold puts Aardvark Prader-Willi drug in limbo

    The company plans to unblind the late-stage study that was halted due to safety concerns, which could lead to an overhaul of its entire development program.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers

    Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted immune drug.

  • Orange packages of mifepristone tablets rest against each other on a table.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip
    Trump administration

    Supreme Court preserves access to abortion pill by mail

    The ruling maintains access to the drug while litigation continues. Mifepristone can still be prescribed at pharmacies or by mail without requiring in-person visits.

  • An illustration of necrotic muscle fiber in Duchenne muscular dystrophy.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    With new data, Regenxbio to seek FDA approval of Duchenne gene therapy

    Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA leadership will have a “mandate on rare disease flexibility.”

  • A sign with Biogen's logo sits outside the company's Cambridge, Massachusetts, headquarters on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Biogen pushing tau drug forward despite Alzheimer’s study failure

    One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.

  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Create Medicines raises $122M to bolster in vivo CAR-T therapies

    The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.

  • man in a dark blue suit speaks in the oval office
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip
    Trump administration

    FDA’s leadership void leaves biotech with renewed ‘uncertainty’

    Marty Makary's resignation leaves the agency with temporary directors in three top positions, and a number of newly instituted policies with an unclear future.

    FDA
  • A person in a dark business suit sits at a desk with a microphone.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip
    Trump administration

    FDA chief Marty Makary resigns from agency, ending tumultuous tenure

    Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with drugmakers.  

    FDA
  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    Bristol Myers’ alliance with Hengrui ranks as the second-largest licensing pact of its kind since the start of 2025, trailing only AstraZeneca’s $18.5 billion tie-up with CSPC in January, according to BioPharma Dive data.

    Updated May 19, 2026
  • A sign spelling Bristol Myers Squibb hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion

    The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts. 

  • A sign with Eli Lilly's logo sits outside of the company's headquarters on March 17, 2024 in Indianapolis.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss

    A pair of trial results published in medical journals suggest switching from high-dose injectables to lower doses or pills could help people with obesity keep their weight down over the long term.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B

    Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.